Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors
September 30 2019 - 12:35PM
Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Dr.
David Wheadon has been appointed to the Company’s Board of
Directors. Dr. Wheadon is a former senior executive of AstraZeneca
plc.
“David is a globally recognized leader in healthcare and we are
thrilled to have him join our Board of Directors,” said Arthur
Higgins, President and CEO of Assertio. “David’s perspectives, both
as a physician and as an executive with significant and broad
industry expertise, will add further depth and breadth to our
Board.”
“I am excited to serve on Assertio’s Board and contribute to its
ongoing transformation into a leading diversified biopharmaceutical
company,” said Dr. Wheadon.
Dr. Wheadon is a former senior executive of AstraZeneca plc,
having recently retired as Senior Vice President, Global Regulatory
Affairs, Patient Safety and Quality Assurance. Dr. Wheadon has held
many leadership roles in the healthcare sector, including:
Executive Vice President, Research and Advocacy at the Juvenile
Diabetes Research Foundation; Senior Vice President, Scientific and
Regulatory Affairs at PhRMA; Senior Vice President of Global
Pharmaceutical Regulatory and Medical Sciences at Abbott
Laboratories; Senior Vice President of U.S. Regulatory Affairs at
GlaxoSmithKline Pharmaceuticals; Vice President and Director CNS/GI
Clinical Research at SmithKline Beecham Pharmaceuticals; and
Clinical Research Physician at Eli Lilly and Company. Dr.
Wheadon has been integral to the successful development and
approval of several important drugs for central nervous system
diseases, diabetes, gastrointestinal disorders and diseases in
other therapeutic areas.
Dr. Wheadon holds a M.D. from Johns Hopkins University School of
Medicine and an A.B. in Biology from Harvard University. He
completed his postdoctoral training in Psychiatry at Tufts/New
England Medical Center in Boston, Massachusetts.
About Assertio Therapeutics, Inc.Assertio
Therapeutics is committed to providing responsible solutions to
advance patient care in the Company’s core areas of neurology,
orphan and specialty medicines. Assertio currently markets three
FDA-approved products and continues to identify, license and
develop new products that offer enhanced options for patients that
may be underserved by existing therapies. To learn more about
Assertio, visit www.assertiotx.com.
"Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995This news release contains
forward-looking statements. These statements involve inherent risks
and uncertainties that could cause actual results to differ
materially from those projected or anticipated, including risks
outlined in the Company's public filings with the Securities and
Exchange Commission, including the Company's most recent annual
report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
All information provided in this news release speaks as of the date
hereof. Except as otherwise required by law, the Company undertakes
no obligation to update or revise its forward-looking
statements.
Investor and Media Contact:John B. Thomas SVP,
Investor Relations and Corporate Communications
jthomas@assertiotx.com
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Sep 2023 to Sep 2024